These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 1877538)

  • 21. Clinically significant heparin carryover on the ACL 300R.
    Karsan A; MacLaren I; Pi D; Wadsworth L
    Am J Clin Pathol; 1992 Aug; 98(2):240-2. PubMed ID: 1510037
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correlation between activated clotting time and activated partial thromboplastin times.
    Smythe MA; Koerber JM; Nowak SN; Mattson JC; Begle RL; Westley SJ; Balasubramaniam M
    Ann Pharmacother; 2002 Jan; 36(1):7-11. PubMed ID: 11816262
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The use of ecarin chromogenic assay and prothrombinase induced clotting time in the monitoring of lepirudin for the treatment of heparin-induced thrombocytopenia.
    Guy S; Kitchen S; Laidlaw S; Cooper P; Woolley A; Maclean R
    Br J Haematol; 2008 Jul; 142(3):466-8. PubMed ID: 18510685
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activated partial thromboplastin time and anti-xa measurements in heparin monitoring: biochemical basis for discordance.
    Takemoto CM; Streiff MB; Shermock KM; Kraus PS; Chen J; Jani J; Kickler T
    Am J Clin Pathol; 2013 Apr; 139(4):450-6. PubMed ID: 23525615
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monitoring heparin therapy using activated partial thromboplastin time--results of a multicenter trial establishing the therapeutic range for SILIMAT, a reagent with high sensitivity to heparin.
    Toulon P; Boutière B; Horellou MH; Trzeciak MC; Samama MM
    Thromb Haemost; 1998 Jul; 80(1):104-8. PubMed ID: 9684794
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The optimum number and types of plasma samples necessary for an accurate activated partial thromboplastin time-based heparin therapeutic range.
    Marlar RA; Gausman J
    Arch Pathol Lab Med; 2013 Jan; 137(1):77-82. PubMed ID: 23276178
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recommendations for appropriate activated partial thromboplastin time reagent selection and utilization.
    Fritsma GA; Dembitzer FR; Randhawa A; Marques MB; Van Cott EM; Adcock-Funk D; Peerschke EI
    Am J Clin Pathol; 2012 Jun; 137(6):904-8. PubMed ID: 22586049
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of two APTT methods of monitoring heparin therapy. APTT ratio and heparin response of pooled normal plasma.
    Zanke B; Shojania AM
    Am J Clin Pathol; 1990 May; 93(5):684-9. PubMed ID: 2183588
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Verification of the guidelines for lupus anticoagulant detection: usefulness of index for circulating anticoagulant in APTT mixing test.
    Kumano O; Ieko M; Naito S; Yoshida M; Takahashi N; Suzuki T; Aoki T
    Thromb Res; 2014 Aug; 134(2):503-9. PubMed ID: 24935674
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The therapeutic range for heparin therapy: relationship between six activated partial thromboplastin time reagents and two heparin assays.
    Kitchen S; Preston FE
    Thromb Haemost; 1996 May; 75(5):734-9. PubMed ID: 8725715
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Monitoring heparin therapy: relationships between the activated partial thromboplastin time and heparin assays based on ex-vivo heparin samples.
    van den Besselaar AM; Meeuwisse-Braun J; Bertina RM
    Thromb Haemost; 1990 Feb; 63(1):16-23. PubMed ID: 2339357
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of factor VIII levels on the APTT and anti-Xa activity under a therapeutic dose of heparin.
    Mitsuguro M; Okamoto A; Shironouchi Y; Sano M; Miyata S; Neki R; Araki T; Hamamoto T; Yoshimatsu J; Miyata T
    Int J Hematol; 2015 Feb; 101(2):119-25. PubMed ID: 25416968
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of low dose nitroglycerin on plasma heparin concentrations and activated partial thromboplastin times.
    Brack MJ; More RS; Hubner PJ; Gershlick AH
    Blood Coagul Fibrinolysis; 1993 Feb; 4(1):183-6. PubMed ID: 8457649
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Heparin dosing and monitoring for cardiopulmonary bypass. A comparison of techniques with measurement of subclinical plasma coagulation.
    Gravlee GP; Haddon WS; Rothberger HK; Mills SA; Rogers AT; Bean VE; Buss DH; Prough DS; Cordell AR
    J Thorac Cardiovasc Surg; 1990 Mar; 99(3):518-27. PubMed ID: 2308370
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of different nitrate preparations on plasma heparin concentrations and the activated partial thromboplastin time.
    Brack MJ; More RS; Hubner PJ; Gershlick AH
    Postgrad Med J; 1994 Feb; 70(820):100-3. PubMed ID: 8170877
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activated clotting time versus activated partial thromboplastin time for therapeutic monitoring of heparin.
    Simko RJ; Tsung FF; Stanek EJ
    Ann Pharmacother; 1995 Oct; 29(10):1015-21; quiz 1061. PubMed ID: 8845539
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Monitoring unfractionated heparin therapy: relationship between eight anti-Xa assays and a protamine titration assay.
    Kitchen S; Theaker J; Preston FE
    Blood Coagul Fibrinolysis; 2000 Mar; 11(2):137-44. PubMed ID: 10759006
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Conventional chromogenic heparin assays are influenced by patient's endogenous plasma Antithrombin levels.
    Mitchell LG; Vegh P
    Klin Padiatr; 2010 May; 222(3):164-7. PubMed ID: 20514621
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The activated partial thromboplastin time as a monitor of heparin therapy: a warning.
    Makary AZ; Waterbury L
    Johns Hopkins Med J; 1977 Jun; 140(6):311-5. PubMed ID: 864903
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A review of the clinical indications for the plasma heparin assay.
    Marci CD; Prager D
    Am J Clin Pathol; 1993 May; 99(5):546-50. PubMed ID: 8493948
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.